| Xcovery is creating next generation, targeted, small molecule inflammation and oncology therapeutics. Xcovery’s lead programs, currently in preclinical development, combine world-class medicinal chemistry and biology from academic partners to produce novel, less toxic, and more efficacious kinase therapeutics that feature drug properties that are significantly improved over current existing therapies. |
|
| Xcovery is driven by |
|
| . |
The entrepreneurial leadership of Mr. Sheridan Snyder - founder and former CEO of Genzyme, Upstate Biotechnology, and Biotage.
|
|
| . |
The scientific leadership of Dr. Chris Liang, co-inventor of Sutent® and currently Director of Medicinal Chemistry at The Scripps Research Institute. |
|
|
| Xcovery's pipeline consists of three rapidly moving pre-clinical therapeutic programs: two oncology programs and one pre-clinical inflammation program, each with lead candidate designs a generation ahead of current approaches and products. |
|
| Xcovery is based in West Palm Beach, Florida, and is the first spin-out from the new Scripps Research Institute located in Jupiter, Florida. |
| |
|